MedImmune is currently evaluating MEDI-528 in patients with asthma in a series of Phase II clinical trials. The goal of the current Phase IIa trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction.
The study will also assess the effect of MEDI-528 on exercise challenge testing, as well as the pharmacokinetics and immunogenicity of the investigational treatment. Enrollment of this randomized, double-blind, placebo-controlled trial will take place at multiple sites throughout the US and Canada.
Jack Armstrong, president and CEO of Genaera, said: “The initiation of the exercise-induced bronchoconstriction trial represents another important step in the development of the anti-IL-9 antibody for mild to moderate asthma.”